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Background: In principle, automated systems allow rapid reading of disc diffusion AST (rAST) within 6–8 h.
Objectives: This study analysed whether rAST can discriminate resistance phenotypes such as ESBL, carbapene-
mases and MRSA/methicillin-resistant Staphylococcus epidermidis from WT populations. We describe species–
drug combinations that may require clinical breakpoint adaptions for early reading due to zone diameter
changes during the incubation period.
Methods: In total, 1852 clinical strains [Escherichia coli (n"475), Klebsiella pneumoniae (n"375), Enterobacter
cloacae (n"301), Staphylococcus aureus (n"407) and S. epidermidis (n"294)] were included in this study com-
prising WT populations and important resistance phenotypes, e.g. ESBL, carbapenemases and MRSA. We as-
sessed (i) separation of resistance phenotypes and WT populations after 6, 8 and 12 h as compared with the 18 h
standard, and (ii) diameter changes of WT populations and associated putative epidemiological cut-offs during
the incubation period. Disc diffusion plates were automatically streaked, incubated and imaged using the
WASPLabTM system.
Results and conclusions: We demonstrated that important resistance phenotypes could reliably be separated
from WT populations at early reading times for the most prevalent bacterial pathogens encountered in the clin-
ical laboratory. Current AST expert rules and algorithms for identification of resistance mechanisms can readily
be applied for rAST, e.g. EUCAST recommended rules for detection of ESBL, AmpC, carbapenemases and
MRSA/methicillin-resistant S. epidermidis. However, several species–drug combinations may require clinical
breakpoint adaptations when using rAST as the diameter, and hence the epidemiological cut-off, changes during
the incubation period.
Introduction
Detection of important antibiotic resistance mechanisms such as
ESBL, AmpC b-lactamases, carbapenemases, MRSA or inducible
ermMLS (iMLS) is critical to ensure a successful clinical outcome.
1–5
Rapid implementation of effective, targeted antibiotic treatment
significantly improves clinical outcome and reduces mortality.6–8
Automated microdilution AST provides results within 6–12 h but
carries several disadvantages such as non-flexible drug panels,
few drug concentrations tested, minimal detection of synergism/
antagonism phenomena and a comparably low sensitivity/specifi-
city for the detection of important resistance mechanisms such as
ESBL, carbapenemases or iMLS.9–11 Molecular detection of resist-
ance determinants is rapid and focused on specific genetic targets,
but accurate coverage of the most relevant resistance genes is a
laborious task. In addition, the presence of a gene may not correl-
ate with phenotypic expression and off-panel or emerging resist-
ance determinants are readily missed by molecular assays.12
Disc diffusion is an accurate, reliable and highly standardized
AST method with the advantages of low consumable costs and
flexible drug panels. Procedures to detect reliably the important re-
sistance mechanisms and their associated phenotypes using disc
diffusion AST have been established. Current disc diffusion based
on EUCAST and CLSI guidelines requires incubation times of
16–18 h for most species–drug combinations.5,13–15
We recently demonstrated that early reading of disc diffusion is
in principle possible by using automated systems.16 This study
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aimed to (i) analyse the potential of rapid disc diffusion AST (rAST),
i.e. early zone diameter reading at 6–12 h, to discriminate import-
ant resistance phenotypes from WT populations, and (ii) to de-
scribe species–drug combinations for which clinical breakpoint
(CBP) changes are necessary for early reading due to changes of
zone diameters during the incubation period. Diameter changes of
the WT result in shifts of corresponding epidemiological cut-offs
(ECOFFs), which are a critical parameter in CBP setting.17
Methods
Clinical isolates
Study isolates were selected to cover a broad range of inhibition zone diam-
eters (6–40 mm) for each species/drug combination tested (see Figure S1,
available as Supplementary data at JAC Online). In particular, critical iso-
lates close to the CBPs were included. All non-duplicate clinical strains
included in this study were isolated over a 3 year period from 2013 to 2016
in the clinical microbiology laboratory of the Institute of Medical
Microbiology, University of Zurich. Isolates of the same species were
considered duplicate(s) if they (i) originated from the same patient, and
(ii) showed one major and two minor differences in AST interpretation at
maximum. The following numbers of clinical isolates were tested:
Escherichia coli (N"475), Klebsiella pneumoniae (N"375), Enterobacter
cloacae (N"301), Staphylococcus aureus (N"407) and Staphylococcus
epidermidis (N"294).
Quality control strains
To control for methodological precision, E. coli ATCC 25922 and S. aureus
ATCC 29213 EUCAST quality control strains were tested daily from individual
fresh sub-cultures and individually prepared McFarland 0.5 standards.
Interpretation was done according to EUCAST QC tables, version 6.1.18
Quality control ranges and targets were met during this study (data not
shown).
Definition of phenotypes
Resistance phenotypes and the WT populations were defined as per criteria
given in Table S1. Assignment of phenotypes was done prior to this study
based on independent disc diameter measurements generated by using
the EUCAST recommended method on Mueller–Hinton II agar (Becton-
Dickinson, Franklin Lakes, NJ, USA), with antibiotic discs from i2a (i2a,
Montpellier, France), and applying EUCAST CBPs.19 Inhibition zone diam-
eters were recorded using the Sirscan/Sirweb system (i2a). Phenotypic
screening and confirmation for the detection of AmpC, ESBL and carbape-
nemases by combination disc testing was performed as previously
described.13–15
Automated susceptibility testing
Susceptibility testing was performed as described previously according to
EUCAST guidelines version 6.0,19 which are essentially the same as that of
CLSI 2016.16,20 In brief, bacterial suspensions were manually adjusted to
0.5 McFarland and processed within 15 min. Mueller–Hinton II agar plates
(Oxoid Limited, Basingstoke, UK) were processed in the fully automated
WASPTM (Copan Italia, S.p.A., Brescia, Italy), i.e. plates were each inoculated
with 60lL of the bacterial suspension and automatically streaked.
Antibiotic discs of a single production lot (Oxoid Limited) were placed using
a standard distributor, which was handled by the WASPTM robot immedi-
ately after plate streaking. Subsequently, plates were automatically trans-
ported to and incubated in a WASPLabTM incubator (Copan) at 36+2C in
ambient air. Images were taken after 6, 8, 12 and 18 h of incubation under
continuous temperature conditions. Diameter measurements were
automatically done by the WASPLabTM reading software (Copan) and were,
if necessary, adjusted on-screen by an experienced technician.
Statistical analyses
All statistical analyses were performed using R, version 3.2.3.21 The R pack-
age pROC, version 1.8, was used to calculate areas under the receiver oper-
ating characteristic curve.22
Results
Detection of major resistance mechanisms
In the following, the terms ‘well-separated/well-discriminative’ in-
dicate separation of WT and non-WT populations with a sensitivity
and specificity of at least 0.95 (shown by non-overlapping boxes in
Figure S1). ‘Fully separated/discriminative’ means separation with
a sensitivity and specificity of 1 (whiskers in Figure S1 do not over-
lap). ‘Not separable’ indicates separation of WT and non-WT popu-
lation with sensitivity and specificity both .0.95 is not possible
(overlapping boxes in Figure S1).
Detection of major resistance mechanisms was readily possible
after 6–8 h using the same screening drugs that are used for con-
ventional 18 h incubation AST. ESBL, AmpC, carbapenemases,
MRSA and quinolone resistance were reliably detected at early
timepoints using EUCAST- and CLSI-recommended marker antibi-
otics, i.e. with sensitivity and specificity of at least 0.95 (see
Table 1).
Change of WT zone diameters and discrimination of WT
from non-WT during the incubation period
WT zone diameter changes during the incubation period were de-
pendent on species–drug combinations: for 34 of 44 enterobacterial
species–drug combinations (77.3%), the fifth percentile of the WT
zone diameters (used as a surrogate for the ECOFF, see Figure 1) re-
mained stable during the incubation period, i.e. it showed an
absolute diameter change of 2 mm between 6 h and 18 h. For 7
Table 1. Early detection of major resistance mechanisms by screening
drugs
Resistance mechanisms/
organism groups
Screening
drug
Applicablea
at 6/8 h
Applicablea
at 18 h
Enterobacteriaceae
ESBL ceftriaxone yes yes
cefpodoxime yes yes
AmpC cefoxitin yes yes
carbapenemases (general) meropenem yes yes
OXA-48-like enzymes temocillin yes yes
quinolone resistance
(high level)
norfloxacin yes yes
Staphylococci
PBP2a cefoxitin yes yes
quinolone resistance
(high level)
norfloxacin yes yes
aApplicability refers to a sensitivity and specificity of at least 0.95.
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Figure 1. Change of WT zone diameters and putative ECOFFs during the incubation period. Graphs depict the fifth percentile of the WT population.
This value is used as surrogate for the ECOFF. Increasing values (yellow lines) or decreasing values (red lines) depict an absolute diameter change
of.2 mm between 6 h and 18 h. Stable values (absolute diameter change of2 mm between 6 h and 18 h) are displayed in green.
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of 44 enterobacterial species–drug combinations, i.e. 15.9%, the
ECOFF increased by .2 mm. For trimethoprim/sulfamethoxazole
we observed a decrease of the ECOFF during the incubation period
(3 of 44 combinations, i.e. 6.8%). In contrast, we observed increas-
ing ECOFF for staphylococci irrespective of the drug analysed
(Figure 1).
b-Lactams
Enterobacteriaceae
Susceptibility to ampicillin in principle discriminated b-lactamase
producers from the WT independently from the reading time with
readability ranging from 96% to 100% (accounts for E. coli only as
K. pneumoniae and E. cloacae harbour chromosomal SHV and
AmpC enzymes, respectively, Figure 2 and Figure S1). ESBL produ-
cers were well separated from the WT at 6–8 h by cefpodoxime or
ceftriaxone diameters independent of the Enterobacteriaceae spe-
cies. Cefoxitin was discriminative for the presence of acquired
AmpC b-lactamases in E. coli and K. pneumoniae. For amoxicillin/
clavulanate, piperacillin/tazobactam, cefuroxime and cefepime,
no differences in separability were detected between early and
18 h reading times for the b-lactamase phenotypes. Meropenem
susceptibility at early reading times separated class A, B and D car-
bapenemases effectively, i.e. KPC, NDM, VIM or OXA-48 producers
in the three Enterobacteriaceae species analysed. Temocillin
was found to detect OXA-48 enzymes at 6–8 h since WT and OXA-
48-positive populations appeared fully separated. In general,
b-lactam zone diameters showed a mixed pattern of stable and
increasing zones (Figure 1).
Staphylococci
Benzylpenicillin separated the majority of blaZ penicillinase-
producing S. aureus from the WT well at 8 h, while populations
were not separated after 6 h (Figure S1). MRSA were well separated
at 6–8 h from methicillin-susceptible S. aureus by cefoxitin suscep-
tibility, S. epidermidis PBP2a-positive non-WT and S. epidermidis
WT populations were not separable at any reading times.
Fluoroquinolones
Enterobacteriaceae
Fluoroquinolone-resistant non-WT populations were well-separated
from the corresponding WT populations at 6 h and fully separated
at 8 h for all fluoroquinolones tested and all Enterobacteriaceae spe-
cies (Figure 2 and Figure S1). Zone diameters increased in all Entero-
bacteriaceae species, except for K. pneumoniae with levofloxacin,
for which stable inhibition zones were observed (Figure 1).
Staphylococci
Norfloxacin was fully discriminative for fluoroquinolone-resistant
non-WT populations from WT S. aureus at 6–8 h and for S. epidermidis
at 8 h (Figure 3 and Figure S1).
Aminoglycosides
Enterobacteriaceae
Non-WT and WT populations were separated well at 6–8 h in all
Enterobacteriaceae species tested (Figure 2 and Figure S1), and
WT zone diameters remained stable during the incubation period
for all species (Figure 1).
Staphylococci
Non-WT and WT populations were well discriminated at 6–8 h in
S. aureus and S. epidermidis.
Tetracyclines
Staphylococci
The tetracycline non-WT was well-discriminated from the WT at
6–8 h in S. aureus but was not separable in S. epidermidis.
The minocycline non-WT and WT populations were not separable
at 6–8 h for S. epidermidis and S. aureus (Figure 3 and Figure S1).
Tigecycline non-WT staphylococcal isolates were not available in
this study.
Drug
6 h 18 h 6 h 18 h 6 h 18 h 6 h 18 h 6 h 18 h 6 h 18 h 6 h 18 h
Proportion of
resistant
phenotypes
(% of isolates)
E.coli
Proportion of
resistant
phenotypes
(% of isolates)
K. pneumoniae
Proportion of
resistant
phenotypes
(% of isolates)
E. cloacae
ESBL
acquired AmpC or AmpC
hyperproduction
class A carbapenemases
(KPC type)
Resistance phenotype separation from wild type (95% probability level) at 6 and 18 h
class B beta-lactamases
(NDM and VIM type)
class D beta-lactamases
(OXA-48 type)
high-level quinolone
resistance
non-WT
without specified
mechanism
Ampicillin 78
78
78
78
78
78
66
66
66
26
37
57
2
98
78
78
NA
38
38
37
37
37
54
54
54
20
31
36
11
26
37
37
NA
NA
83
83
83
83
39
39
39
29
31
41
1
81
83
NA
Amoxicillin clavulanate
Piperacillin/tazobactam
Temocillin
Cefuroxime
Cefoxitin
Cefpodoxime
Ceftriaxone
Cefepime
Meropenem
Norfloxacin
Ciprofloxacin
Levofloxacin
Gentamicin
Tobramycin
Trimethoprim/sulfamethoxazole
Figure 2. Separation of non-WT and WT populations at 6 h versus 18 h of incubation: Enterobacteriaceae. Green boxes, WT and non-WT populations
were well separated (i.e. separation with sensitivity and specificity at least 0.95 is possible); red boxes, WT and non-WT populations were not sepa-
rated (i.e. separation with sensitivity and specificity at least 0.95 is not possible); yellow boxes, separability of WT and non-WT populations differs
among species; proportion of resistant phenotypes: according to the EUCAST recommended method on Mueller–Hinton II agar; NA, not applicable.
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MLS drugs
Staphylococci
Erythromycin was well to fully discriminative for the constitutive
macrolide lincosamide streptogramin (MLS) and iMLS phenotype
for all reading times and both staphylococcal species analysed
(Figure 3 and Figure S1). For clindamycin, the constitutive MLS non-
WT of S. aureus was well-separated from the WT at all reading
times. In S. epidermidis well-separated populations were detected
after 18 h only. The iMLS phenotype could not be discriminated by
diameter values at all reading times but induction phenomena
(D-shape test) were readily detected at early reading times.
Miscellaneous drugs
Enterobacteriaceae
Trimethoprim/sulfamethoxazole non-WT populations were well-
separated from the WT at all reading times for the Enterobacteria-
ceae (except for K. pneumoniae at 6 h, see Figure 2 and Figure S1).
Staphylococci
Trimethoprim/sulfamethoxazole and rifampicin non-WT popula-
tions were well-separated from the WT at all reading times for
S. epidermidis. For S. aureus discrimination was possible after 18 h
only. Fusidic acid non-WT populations were discriminated from the
WT at early (8 h) and late reading times for S. epidermidis and
S. aureus (Figure 3 and Figure S1).
Discussion
rAST allowed the timely detection of important resistance pheno-
types in the bacterial species that are most frequently encountered
in the clinical laboratory. Rapid detection of major resistance mech-
anisms was readily possible for important drug classes used in
patients with life-threatening infections (Figures 1 and 2, Table 1).
Basically the same expert rules used for the detection of important
resistance mechanisms at 18 h can be applied to rAST, e.g.: (i) cef-
podoxime and ceftriaxone were good predictors for the presence of
ESBL; (ii) cefoxitin was a good predictor for the presence of acquired
AmpC type b-lactamases; (iii) meropenem was a sensitive marker
for the presence of any type of carbapenemase; (iv) norfloxacin
was a good predictor of fluoroquinolone resistance; (v) cefoxitin
was a good marker for MRSA detection; and (vi) iMLS-based clinda-
mycin resistance required additional parameters such as the
D-shape test to be detected.5,13–15,18,20,23 Based on our analyses,
the non-WT population zone diameter values are well separated at
6–8 h from WT population diameters for the most important drug
classes and resistance phenotypes. In principle, this will allow for
reliable resistance phenotype prediction at early timepoints.
Of note, the WASPLabTM automated incubators in the setting of
our laboratory did not allow separation of the primary culture plates
from the disc diffusion plates. This limitation could be overcome by
dedicating a specific incubator to 35C for disc diffusion AST.
However, this seems impractical for most laboratories due to lim-
ited space and for cost reasons. We therefore applied an incubation
temperature of 36C as a compromise, but ran EUCAST QCs daily to
ensure calibration to EUCAST QC ranges. EUCAST mainly recom-
mends incubation at 35C to improve detection of MRSA, and in the
present study, all 51 MRSA isolates were readily detected at 36C.
This study was not intended to issue general rAST guidelines. We
rather used our local epidemiology as a paradigmatic example to in-
vestigate the challenges of rAST. Aggregated datasets from different
geographies will be needed to develop general guidelines for rAST
similar to current EUCAST procedures for CBP setting.24 However,
rapid disc diffusion data may be analysed in a systematic way:
(i) If non-WT strains cannot safely be discriminated from the WT
population at early reading times, a grey zone covering the
8 h 18 h 8 h 18 h 8 h 18 h 8 h 18 h 8 h 18 h 8 h 18 h
Proportion of
resistant
phenotypes
(% of isolates)
S. aureus
Proportion of
resistant
phenotypes
(% of isolates)
S. epidermidis
blaZ penicillinase PBP2a high-level quinolone
resistance
Resistance phenotype separation from wild type (95% probability level) at 8 and 18 h
constitutive ermMLS inducible ermMLS non-WT without
specified mechanism
60
24
15
55
3
8
10
1
9
2
5
0
15
15
15
42
NA
88
62
46
54
57
21
1
51
14
47
0
59
62
62
25
Drug
Benzylpenicillin
Cefoxitin
Norfloxacin
Ciprofloxacin
Levofloxacin
Clindamycin
Erythromycin
Gentamicin
Tobramycin
Minocycline
Tetracycline
Kanamycin
Fusidic acid
Rifampicin
Trimethoprim/sulfamethoxazole
Linezolid
Figure 3. Separation of non-WT and WT populations at 8 h versus 18 h of incubation: staphylococci. For staphylococci, the 8 h reading was selected
for comparison with 18 h readings as readability was higher at 8 h (see Figure S1). Green boxes, WT and non-WT populations were well separated
(i.e. separation with sensitivity and specificity at least 0.95 is possible); red boxes, WT and non-WT populations were not separated (i.e. separation
with sensitivity and specificity at least 0.95 is not possible); yellow boxes, separability of WT and non-WT populations differs among species; grey
boxes, non-WT populations not available; proportion of resistant phenotypes according to the EUCAST recommended method on Mueller–Hinton II
agar; NA, not applicable.
Rapid disc diffusion susceptibility testing JAC
3067
Downloaded from https://academic.oup.com/jac/article-abstract/72/11/3063/4079888
by University of Zurich user
on 10 November 2017
diameter range of overlapping WT and non-WT populations
may be introduced. Such grey zones would work as a buffer to
prevent categorization errors but would also allow rapid re-
porting of a substantial number of isolates in the non-
overlapping ranges as either susceptible or resistant. Of note,
most problems with overlapping WT and non-WT populations
found in this study were not limited to early reading times but
were also present at standard reading at 18 h, e.g. amoxicillin/
clavulanate or piperacillin/tazobactam and ESBL, or cefoxitin
and PBP2a in S. epidermidis. The concept of technical buffer
zones that has been demonstrated to prevent major and very
major categorization errors for standard incubation, may thus
be a reasonable option for rAST, too.23
(ii) If non-WT strains can safely be discriminated from the WT
populations, it needs to be determined whether WT zone
diameters and the corresponding ECOFFs shift during the in-
cubation period (Figure 1).
(iii) If WT diameters and ECOFFs are stable, current EUCAST CBPs
may readily be applied (34 of 44 species–drug combinations
and Enterobacteriaceae in this study, i.e. 77.3%).
(iv) If ECOFFs shift during the incubation period, CBP adaptations
may be necessary for early reading as shown for staphylo-
cocci that were displaying diameter increases .2 mm (the
fifth percentile of the WT population served as a surrogate
for the ECOFF; Figure 1).
In conclusion, this study demonstrated that: (i) the most im-
portant non-WT populations can be separated from the WT at
early reading times; (ii) the same expert rules for standard incuba-
tion can be used for early reading; and (iii) for several species–drug
combinations, particularly for staphylococci, CBP adaptations at
early reading times may be necessary to ensure adequate
categorization.
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